Aerie Pharmaceuticals is a pioneering company in the field of ophthalmic pharmaceuticals, focusing on the discovery, development, and commercialization of first-in-class therapies for eye diseases. The company primarily targets patients suffering from open-angle glaucoma, ocular surface diseases, and retinal diseases. Aerie Pharmaceuticals operates in the healthcare and pharmaceutical markets, serving both patients and healthcare providers. The business model revolves around extensive research and development (R&D) to create innovative prescription eye drops and other treatments, which are then marketed and sold to healthcare professionals and patients. Revenue is generated through the sale of these prescription medications, which are designed to lower intraocular pressure (IOP) in glaucoma patients and treat other eye conditions. Aerie Pharmaceuticals is committed to environmental stewardship, social responsibility, and good corporate governance, which are integral to its operations and corporate ethos.

Keywords: ophthalmic, glaucoma, ocular surface, retinal diseases, prescription eye drops, intraocular pressure, healthcare, pharmaceutical, innovation, R&D.